Unicycive Therapeutics (UNCY) Return on Assets (2021 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Return on Assets came in at 0.01% in Q1 2026, little changed YoY from 0.01% in Q1 2025, and down 13.59% on a QoQ basis from 0.01% in Q4 2025.
Unicycive Therapeutics (UNCY) Return on Assets (2021 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 6 years of Return on Assets data on file, last reported at 0.01% in Q1 2026.
- Quarterly Return on Assets changed 0.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY) and the FY2025 annual result came in at 0.01%, up 1.0% from the prior year.
- Return on Assets retreated to 0.01% in Q1 2026, from 0.01% in the prior quarter.
- In the past five years, Return on Assets ranged from a high of 0.01% in Q1 2022 to a low of 0.23% in Q4 2023.
- A 5-year average of 0.05% and a median of 0.01% in 2025 frame the typical range for Return on Assets.
- Annual changes were most pronounced in 2023 — Return on Assets fell 20 bps — and 2024, when it climbed 22 bps.
- Tracing UNCY's Return on Assets over 5 years: stood at 0.03% in 2022, then sank by 698 bps to 0.23% in 2023, then soared by 96 bps to 0.01% in 2024, then advanced by 11 bps to 0.01% in 2025, then slipped by 14 bps to 0.01% in 2026.
- The last three Return on Assets figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | 0.00% |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 0.00% |
| 10 | Unicycive Therapeutics | 152.89 Mn | 152.89 Mn | - | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.01% |
| Mar 31, 2026 | -0.01% |
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | -0.01% |
| Dec 31, 2024 | -0.01% |
| Sep 30, 2024 | -0.01% |
| Jun 30, 2024 | -0.01% |
| Mar 31, 2024 | -0.05% |
| Dec 31, 2023 | -0.23% |
| Sep 30, 2023 | -0.18% |
| Jun 30, 2023 | -0.14% |
| Mar 31, 2023 | -0.17% |
| Dec 31, 2022 | -0.03% |
| Sep 30, 2022 | -0.01% |
| Jun 30, 2022 | -0.01% |
| Mar 31, 2022 | -0.01% |
| Dec 31, 2021 | 0.00% |
| Sep 30, 2021 | -0.01% |